Skip to Main Content

Happy Friday! Elizabeth Cooney here from Boston, filling in for Ed Silverman from a campus that the no-longer-short people long ago fled to ply their trades in New York, where the mascots are feline, and in which the coffee is never flavored (and always black). Ed will be back in the Pharmalot castle next week. Thank you for all your comments and tips this week. Here are some more items to ponder:

A little more than a week ago, Amarin (AMRN) said that the Food and Drug Administration was “unlikely” to convene an advisory committee meeting to review data on an expanded use of its heart drug Vascepa, STAT says. But on Thursday, Amarin reversed course, announcing that the FDA has scheduled a Vascepa advisory committee meeting for Nov. 14, raising fears that something might be amiss with the Vascepa clinical trial data.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!